Peter Vanderslice, PhD

Dr. Vanderslice has spent over 20 years leading teams focused on the development of small molecule compounds that bind and modulate the function of integrins and chemokine receptors. The majority of his professional career has been in the pharmaceutical industry, where he gained familiarity with each stage of the pipeline from discovery to progression into clinical trials. Dr. Vanderslice has led teams working on several pre-clinical programs involving efforts in drug screening, lead compound characterization, and the development of preclinical animal models.

See Publications

Texas Heart Institute Positions

Interests

  • Non-invasive diagnostic imaging technologies

Education

  • Undergraduate:

    University of Maryland

  • Postgraduate:

    University of Texas at Austin (PhD)

  • Fellowships:

    University of California San Francisco

Honors, Awards and Memberships

  • Parker B. Francis Fellowship in Pulmonary Research, University of California, San Francisco, CA

Publications

Recent News

Texas Heart Institute & 7 Hills Pharma awarded a $1.9 million grant from National Heart Lung Blood Institute to improve stem cell transplantation

HOUSTON, TX (June 11, 2020) —The Texas Heart Institute and 7 Hills Pharma (7 Hills) received a $1.9 million, Phase...

Texas Heart Institute’s molecular discovery at the heart of a new vaccine development program

A promising molecular technology co-invented by scientists at the Texas Heart Institute and 7 Hills could soon enhance the effectiveness...

Texas Heart Institute Discovery to Enhance the Immune System Moves Closer to Clinical Testing

A promising technology invented at the Texas Heart Institute is one step closer to being tested in a clinical study...